MétaCan
Menu
Back to cohort
Record W4411135651 · doi:10.1016/j.esmoop.2025.105125

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

2025· article· en· W4411135651 on OpenAlexfundno aff
S. Nag, Isabelle Ray Coquard, Ashish Pathak, Resti Mulya Sari, Kenichi Harano, G M Kim, S.F. Ang, Florencia G. Que, Wen-Yee Chay, H-C Lai, Touch Ativitavas, Siriwan Tangjitgamol, Valerie Heong, J. Tolentino, M R Ngu, Mayu Yunokawa, Widyorini Lestari Hutami Hanafi, Jian‐Mei Li, Elizabeth Smyth, Takayuki Yoshino, G. Pentheroudakis, Andrés Cervantes, Maheboob Basade, A. Oaknin

Bibliographic record

VenueESMO Open · 2025
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsnot available
FundersFoundation MedicineBayer YakuhinMSD K.K.Chugai PharmaceuticalPfizer JapanEMD SeronoAstraZenecaGenentechCouncil of Scientific and Industrial Research, IndiaSierra OncologySanofi K.K.INCLIVA Instituto de Investigación SanitariaExelixisInternational Atomic Energy AgencyPharmaMarDaiichi Sankyo EuropeTakeda OncologyEuropean Society for Medical OncologyNovocureSeoul National UniversityIndian Council of Medical ResearchIntas PharmaceuticalsSeagenEuropean SocieTy for Radiotherapy and OncologyGlenmark PharmaceuticalsThe Wellcome Trust DBT India AllianceSeoul National University HospitalMacroGenicsSociedad Española de Oncología MédicaBeiGeneActuate TherapeuticsRibon TherapeuticsSysmex CorporationMersana TherapeuticsAmgenAstellas PharmaDeciphera PharmaceuticalsClovis OncologyNateraRegeneron PharmaceuticalsBoehringer Ingelheim JapanGilead SciencesTaiho PharmaceuticalEQRxF. Hoffmann-La RocheServierEisaiFibroGenOno PharmaceuticalEli Lilly and CompanyBristol-Myers SquibbAmerican Society of Clinical OncologyHellenic Society of Medical OncologySanofiPfizerCelgene
KeywordsGuidelineReimbursementMedicineFamily medicineChinaPolitical scienceHealth carePathology

Abstract

fetched live from OpenAlex

The European Society for Medical Oncology (ESMO) Clinical Practice Guideline for the diagnosis, treatment and follow-up of patients with newly diagnosed and relapsed epithelial ovarian cancer (EOC), published in 2023, was adapted in July 2024, according to established standard methodology, to produce the Pan-Asian adapted ESMO consensus guideline for the management of Asian patients with EOC. The adapted guideline presented in this manuscript represents the consensus opinions reached by a panel of Asian experts in the treatment of patients with EOC representing the oncological societies of China, Indonesia, India, Japan, Korea, Malaysia, the Philippines, Singapore, Taiwan and Thailand, coordinated by ESMO and the Indian Society of Medical and Pediatric Oncology. Voting was based on scientific evidence and was independent of current treatment practices, drug access restrictions and reimbursement decisions in the represented countries. Drug access and reimbursement across Asia are discussed separately in the manuscript. The Pan-Asian consensus aims to guide the optimisation and harmonisation of management of patients with EOC in Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between countries.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.638
Threshold uncertainty score0.606

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.379
Teacher spread0.348 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicOvarian cancer diagnosis and treatmentFrench-language works237,207